Mony Fraer, MD
Nephrology · Iowa City, IANPI 1497845960
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,384 of the $4,630 with a category attached, or 73.1%. 10 manufacturers reported payments, led by ZOLL Medical Corporation at 28.0% of the total. Reporting peaked in 2021 at $1,257 and has fallen 69.8% since, to $379 in 2025.
Across 18 payments — averaging $257.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Medical Corporation$1K
- Vertex$729
- Alnylam Pharmaceuticals Inc.$610
- AbbVie$496
- Sanofi-aventis U.S. LLC$350
- Vifor (international) Ltd.$300
- plus $850 from 4 others
Across 3 payments — averaging $17,434 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$30K
- AstraZeneca$22K
What the payments were for
- Consulting fees$3,38473%
- Speaking & faculty fees$1,24627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Medical Corporation | 4 | $1,295 |
| Vertex | 2 | $729 |
| Alnylam Pharmaceuticals Inc. | 2 | $610 |
| AbbVie | 3 | $496 |
| Sanofi-aventis U.S. LLC | 1 | $350 |
| Vifor (international) Ltd. | 1 | $300 |
| BD | 1 | $270 |
| AstraZeneca | 1 | $200 |
| Vifor Pharma, Inc. | 1 | $200 |
| GSK | 2 | $180 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Defibrillator$963
- THYMOGLOBULIN$350
- LEMTRADA$350
- Veltassa$200
How this compares
$4,630 in reported general payments places this provider in the 85th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 18 | $6,821 |
| Sevelamer Carbonate | 14 | $4,369 |
| Tacrolimus | 41 | $3,990 |
| Cinacalcet Hcl | 25 | $1,583 |
| Nifedipine ErNifedipine | 47 | $1,054 |
| Calcium Acetate | 12 | $510 |
| Prednisone | 114 | $417 |
| Hydralazine Hcl | 18 | $396 |
| Midodrine Hcl | 11 | $359 |
| Carvedilol | 58 | $308 |
| Pantoprazole Sodium | 13 | $214 |
| Omeprazole | 17 | $210 |
| Potassium Chloride | 14 | $191 |
| Losartan Potassium | 26 | $167 |
| Doxazosin Mesylate | 17 | $155 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Iowa City
- Lawrence HunsickerIowa City$70K
- Lama NoureddineIowa City$7K
- Benjamin GriffinIowa City$6K
- Kantima PhisitkulIowa City$432
- Masaaki YamadaIowa City$271
- Waleed HassanIowa City$203
- Shahed AmmarIowa City$132
- Bahjat AzriehIowa City$119
- Timothy ChowIowa City$106
- Duha JweehanIowa City$91
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.